N/A N=40 Pupillary Pain Index to Evaluate Interscalene Block and Postoperative Pain in Patients Underwent Shoulder Surgery
Surgery · Shoulder Impingement
Primary: Pupillary Pain Index (PPI ) — 1.8; 6.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 A Trial of Online LGBTQ-affirmative Cognitive Behavioral Therapy to Reduce Depression and Associated Health Risks Among Young Adults
LGBTQ · Sexual Behavior
Primary: Change in Distress — 1.43; 1.57; 1.22; 1.34 score on a scale
Phase 2 N=4 Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
Familial Cold Autoinflammatory Syndrome
Primary: Ratio of Fold Change From Pre-challenge to the Highest Post-challenge Value of White Cell Count (WCC) Between Treatment and Screening Period — 0.82 ratio of fold change
N/A N=284 Optimizing Functional Recovery of Breast Cancer Survivors
Breast Cancer Female
Primary: Participation Satisfaction in Social Roles and Activities: PROMIS — 45.75; 46; 48.09; 47.61 T-score — p=.54
N/A N=300 DIstal vs Proximal Radial Artery Access for Cath
Coronary Angiography · Coronary Angioplasty
Primary: Quick Disabilities of the Arm Shoulder and Hand (DASH) Questionnaire Score (0-100) — 0; 0 DASH Score change from baseline
Phase 4 N=77 Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
Healthy
Primary: Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10 — 1.9; -1.5; -3.6; -3.5 milliseconds (msec)
N/A N=181 ROSA Robot Used in Total Knee Replacement Post Market Study
Knee Pain · Chronic Osteoarthritis · Avascular Necrosis of the Femoral Condyle
Primary: Clinical Performance — .540; .442; .740; .763 score on a scale
Phase 1 N=34 BIO 300 Oral Powder Safety and Pharmacokinetics
Acute Radiation Syndrome
Primary: Adverse Events Related to BIO 300 Oral Powder — 0; 0; 0; 0 Number of Adverse Events
N/A N=542 Helping Hypertension Patients to Interpret Blood Pressure Readings and Motivate Blood Pressure Control
Hypertension
Primary: Number of Participants Who Measured Blood Pressure as Instructed (Assessed on Questionnaire) — 34; 47; 50 Participants — p==0.05
N/A N=20 Patient Centered Postpartum Contraception App
Contraceptive Usage
Primary: Feasibility of Application — 4.47; 4.52; 4.16; 4.26 units on a scale
N/A N=19 Sex and Obesity: Effects on Heart Failure Study
Obesity · Heart Failure
Primary: Average Myocardial Blood Flow — 0.73; 0.97 mL/g/minute — p=<0.005
N/A N=89 The Effects of a Music Intervention on Stress, Anxiety and Academic Performance on Nursing Students
Stress
Primary: Heart Rate Measurement — 83.45; 82.80; 81.88; 84.38 beats per minute
Phase 1 N=600 MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Solid Tumors
Primary: Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 4; 3 Participants
Phase 2 N=100 Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Non-Small Cell Lung Cancer · Epigenetic Therapy
Primary: Objective Response — 4; 1; 5; 3 Participants
Phase 1 N=17 A Study of LAM-003 in Patients With Acute Myeloid Leukemia
Oncology · Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs